Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia

Table 2

Univariable and multivariable analyses of predictors of overall survival.

Variables	Univariable			Multivariable
	HR	95% CI	value	HR	95% CI	value
Age ≥60 years	2.203	0.488–9.956	0.305
Gender (male)	1.780	0.589–5.381	0.307
WBC ≥11 × 10^9/L	1.305	0.437–3.899	0.634
Plt ≥1000 × 10^9/L	2.157	0.722–6.443	0.169
CRP ≥0.30 mg/dL	3.620	1.098–11.980	0.035	2.830	0.837–9.566	0.094
Uric acid ≥7.0 mg/dL	1.595	0.342–7.444	0.552
CKD	3.332	1.113–9.974	0.031	3.750	1.196-11.760	0.023
JAK2V617F mutation	2.546	0.560–11.570	0.226
Chromosome abnormality	All patients with chromosome abnormalities survived
History of thrombosis	2.636	0.873–7.962	0.086
History of hemorrhagic events	1.470	0.188–11.490	0.714
Cardiovascular risk factors	2.351	0.638–8.672	0.199
Splenomegaly	3.680	1.234–10.970	0.019	4.304	1.371-13.520	0.012
Antiplatelet therapy	1.214	0.153–9.639	0.854
Cytoreductive therapy with HU	0.700	0.212–2.311	0.558
Cytoreductive therapy with ANA	0.773	0.167–3.577	0.742

ANA, anagrelide; CI, confidence interval; CKD, chronic kidney disease; HU, hydroxyurea; HR, hazard ratio. values of <0.05 are highlighted in bold.